| Name | Title | Contact Details |
|---|
The home infusion industry turns to KORU Medical Systems to help patients and medical professionals improve infusion therapy experiences and we have a passion and vision for doing just that! We focus on home and specialty infusion solutions, emphasizing responsive problem-solving for our customers with careful consideration to the patient experience. The company was incorporated in March 1980 and is now publicly traded on the NASDAQ Capital Market (NASDAQ: KRMD). We are located in Chester, NY (USA), just 60 miles northwest of New York City. Our primary products include the FREEDOM60® and FreedomEdge® Syringe Infusion Systems, Precision Flow Rate Tubing™, and HIgH-Flo Subcutaneous Safety Needle Sets.
Eastpointe is a Managed Care Organization (MCO) that manages, coordinates, and monitors mental health, intellectual and developmental disabilities, and substance addiction services in the Eastpointe region. We work together with individuals, families, ...
Clene is a clinical-stage biopharmaceutical company focused on the development of unique therapeutics for neurodegenerative diseases. Clene has innovated a novel nanotechnology drug platform for the development of a new class of orally administered neurotherapeutic drugs. Clene has also advanced into the clinic an aqueous solution of ionic zinc and silver for anti-viral and anti-microbial uses. Founded in 2013, the company is based in Salt Lake City, Utah with R&D and manufacturing operations located in North East, Maryland.
Elevar Therapeutics is a rapidly growing, fully integrated biopharmaceutical company built on the promise of elevating treatment experiences and outcomes for patients who have limited or inadequate therapeutic options. Elevar`s lead proprietary drug candidates include rivoceranib (apatinib) and Apealea® (paclitaxel micellar). Rivoceranib is the first small-molecule tyrosine kinase inhibitor (TKI) to be approved in gastric cancer (China, Dec 2014). It has been granted Orphan Drug designation in the U.S., Europe and South Korea and has been clinically tested in over 1,000 patients worldwide in numerous cancer indications. Apealea® (paclitaxel micellar) is a non-Cremophor EL based formulation of paclitaxel that received marketing authorization by the European Commission in November 2018, making it Europe`s first non-Cremophor EL formulation of paclitaxel approved for use in ovarian cancer. Elevar Therapeutics has offices in Utah, California and South Korea.
BC Technical’s leadership team has over 100 years of combined experience in the medical imaging services market.